Seong Jinsil, Han Kwang Hyub, Park Young Nyun, Nam Sun Hye, Kim Sung Hee, Keum Woong Sub, Kim Kyung Sik
Department of Radiation Oncology, Brain Korea 21 Project for Medicine, Yonsei University Medical College, Seoul, South Korea.
Int J Radiat Oncol Biol Phys. 2003 Sep 1;57(1):282-8. doi: 10.1016/s0360-3016(03)00540-6.
To assess lethal hepatic injury by combined treatment of radiation (RT) plus chemotherapy in a rat model with thioacetamide (TAA)-induced liver cirrhosis.
Male Wistar rats were treated with 0.3 g/L TAA in drinking water. The development of liver cirrhosis was histologically confirmed, and the degree of liver function impairment was assessed by indocyanine green retention test (ICG R15). The established cirrhotic rats were given one of the following treatments: partial liver radiotherapy (25 Gy on about one-third of the whole liver), 5-fluorouracil (5-FU) chemotherapy (50 mg/kg), and combined treatment of partial RT plus 5-FU. The treated rats were closely followed until either death or 30 weeks after the treatment, and the postmortem liver sampling was examined for lethal hepatic injury by the treatments.
The rats developed overt liver cirrhosis after 30 weeks of TAA treatment. At that time, the mean ICG R15 level in the TAA-treated rats (TAA-rats) was 14.1% +/- 0.7% compared to 4.6% +/- 0.7% in the control (p < 0.05). The 30-week survival rates in the control and TAA-rats were 100% (5/5) and 75% (6/8), respectively, after partial liver RT (p = 0.72). In the 5-FU chemotherapy group, the survival in TAA-rats was only one-half of that in the controls (100% vs. 50%, p = 0.06). Poor survival in TAA-rats was shown also in the combined group of partial RT plus 5-FU (87.5% vs. 16.7%, p = 0.06). The rats that died before the last observation time showed advanced cirrhosis with areas of lobular collapse, in contrast to the moderate cirrhotic features in those that survived.
In a rat cirrhosis model with mildly impaired liver function, combined treatment of partial RT plus 5-FU resulted in significantly high incidence of lethal liver injury. The results in this study show that a combined treatment of RT plus chemotherapy in cirrhotic patients should be applied with extreme caution.
在硫代乙酰胺(TAA)诱导的肝硬化大鼠模型中,评估放疗(RT)联合化疗所致的致死性肝损伤。
用含0.3 g/L TAA的饮用水处理雄性Wistar大鼠。通过组织学确认肝硬化的发展情况,并通过吲哚菁绿滞留试验(ICG R15)评估肝功能损害程度。对已建立肝硬化的大鼠进行以下治疗之一:部分肝脏放疗(对约全肝的三分之一照射25 Gy)、5-氟尿嘧啶(5-FU)化疗(50 mg/kg)以及部分RT联合5-FU的联合治疗。密切观察接受治疗的大鼠直至死亡或治疗后30周,并对死后肝脏取样检查治疗所致的致死性肝损伤。
TAA治疗30周后大鼠出现明显肝硬化。此时,TAA处理组大鼠(TAA大鼠)的平均ICG R15水平为14.1%±0.7%,而对照组为4.6%±0.7%(p<0.05)。部分肝脏RT后,对照组和TAA大鼠的30周生存率分别为100%(5/5)和75%(6/8)(p = 0.72)。在5-FU化疗组中,TAA大鼠的生存率仅为对照组的一半(100%对50%,p = 0.06)。部分RT联合5-FU的联合组中TAA大鼠的生存率也较低(87.5%对16.7%,p = 0.06)。在最后观察时间之前死亡的大鼠显示出晚期肝硬化伴小叶塌陷区域,而存活大鼠表现为中度肝硬化特征。
在肝功能轻度受损的大鼠肝硬化模型中,部分RT联合5-FU的联合治疗导致致死性肝损伤的发生率显著升高。本研究结果表明,肝硬化患者放疗联合化疗的治疗应极其谨慎应用。